The Effect of COVID-19 Pandemia on Follow up of Patients With Chronic Kidney Disease (COVID19-CKD)

COVID-19 pandemic affected the admission of patients to the hospital especially the older patients (> 65 years old) because of curfews and the reluctance of patients to apply to the hospitals. Chronic kidney disease is characterized with the progressive loss of kidney function over the time and regular follow-up of patients for their kidney function and treatment of complications is recommended in these patients.

Study Overview

• Status: Completed
• Conditions: Covid19; Chronic Kidney Diseases; Proteinuria
• Intervention / Treatment: Other: change in kidney function and proteinuria

Detailed Description

The chronis kidney disease patients followed in Nephrology outpatient unit are going to be enrolled in the study and their kidney functions (calculated with the mdrd formula to asses the estimated glomerular filtration rate (eGFR)) will be evaluated 6 months before and after the COVID-19 pandemia. And the rate of initiation of renal replacement therapies and the change in proteinuria will be evaluated 6 months before and after the COVID-19 pandemic.

• Study Type: Observational
• Enrollment (Actual): 200

Contacts and Locations

Study Locations

• Turkey
  • Usak, Turkey, 64100
    • Uşak University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 85 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

patients with chronic kidney disease (eGFR<60 ml/dk) between the ages 18-80 followed up in nephrology outpatient clinic.

Description

Inclusion Criteria:

• patients with chronic kidney disease on regular follow-up for 6 months before the COVID19 pandemic.

Exclusion Criteria:

• patients without chronic kidney disease
• patients not on routine follow-up for 6 months before the COVID19 pandemic

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
eGFR change	a rise or decrease in eGFR	6 months
change in proteinuria	increase or decrease in ptoteinuria levels	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
initiation of renal replacement therapies	need for hemodialysis or peritoneal dialysis	6 months

Collaborators and Investigators

• Sponsor: Uşak University
• Investigators: Principal Investigator: Zelal Adıbelli, Uşak University

Study record dates

Study Major Dates

• Study Start (ACTUAL): November 3, 2020
• Primary Completion (ACTUAL): December 1, 2020
• Study Completion (ACTUAL): January 1, 2021

Study Registration Dates

• First Submitted: May 2, 2021
• First Submitted That Met QC Criteria: May 2, 2021
• First Posted (ACTUAL): May 6, 2021

Study Record Updates

• Last Update Posted (ACTUAL): May 6, 2021
• Last Update Submitted That Met QC Criteria: May 2, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; Urologic Diseases; Urological Manifestations; Renal Insufficiency; Urination Disorders; COVID-19; Kidney Diseases; Renal Insufficiency, Chronic; Proteinuria
• Other Study ID Numbers: UsakU4

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No